Posted on by Dr Humeira Badsha
In the month-long trial of 200 gout patients, 78% of those receiving the highest dose of canakinumab achieved 75% or more reduction in pain by 72 hours, and 96% had at least a 50% reduction in pain, according to Alexander So, MD, of the University of Lausanne in Switzerland, and colleagues.
In contrast, only 45% of those assigned to triamcinolone acetonide had a 75% reduction in gout pain by 72 hours and 61% had a 50% reduction, So reported during an oral presentation at the annual meeting of the British Society for Rheumatology
This web site is run by an Arthritis Specialist based in Dubai, United Arab Emirates. On this site you will find news about the latest in arthritis, information about research results in the field, tips and information and diet and exercise, and much more.More
The ORBIT data “showed that patients who have seropositive rheumatoid arthritis are just as likely to respond to rituximab therapy when compared ...Read More
Doctors might one day be able to harvest cells from patients’ noses to produce cartilage that can be transplanted into damaged knee joints, a sma...Read More
© 2013 - 2014 Dr.Humeira Badsha. All rights reserved.